Singapore
MASLD Symposium

25 July 2024

8:30 am to 5:00 pm (SGT)

Singapore MASLD Symposium

25 July 2024

8:30 am to 5:00 pm (SGT)

REGISTRATION FOR The Combined GIHep & Singapore Hepatology Conference includes Singapore MASLD Symposium 2024.

The Singapore MASLD Symposium 2024 will feature an extensive line up of World Renowned Experts from Academia AND Industry in the fast developing field of MASLD. They will share and provide a comprehensive update on their research works.

REGISTER HERE for the Combined Conference

To access SHC -e Resources REGISTER HERE or LOG IN (if you have previously registered for SHC)

MEET SOME OF OUR EXPERTS

Singapore MASLD Symposium 2024 Preliminary Scientific Programme

July 2024

25

Advancing Care in MASLD Programme Time (SGT)
Welcome Address
– Prof. Arun SanyalView Bio, Dr. Mark MuthiahView Bio		 08:30 – 08:40
Is MASLD in lean patients the same disease as in overweight and obese individuals? A clinical viewpoint
– Prof. Vincent WongView Bio		 08:40 – 09:00
Is MASLD in lean patients the same disease as in overweight and obese individuals? A pathobiological viewpoint
– Prof. Sven Francque View Bio		 09:00 – 09:20
Similarities and differences between MetALD and MASLD
– Prof. Ajay Duseja View Bio		 09:20 – 09:40
Specific aetiology SLD in the Asian context
– Dr. Daniel Huang QingyaoView Bio		 09:40 – 10:00
Combined Q&A 10:00 – 10:15
Tea Break 10:15 – 10:30
Interpreting NIT data: Lessons from NIMBLE and LITMUS
– Prof. Arun SanyalView Bio		 10:30 – 10:50
Intelligent use of NIT’s in clinical practice – moving forward and back from primary care
– Prof. Chan Wah Kheong View Bio		 10:50 – 11:10
A patient centric view of risk assessment: balancing competing risks
– Dr. Mark MuthiahView Bio		 11:10 – 11:30
Artificial Intelligence in Liver Histology: Driving Development of MASLD Therapeutics
– Prof. Dean Tai 		11:30 – 12:00
Combined Q&A 12:00 – 12:15
Lunch 12:15 – 01:30
Debate: Will incretin-based obesity treatment solve the MASLD epidemic?
– Yes: TBC
– No: Prof. Vincent WongView Bio		 01:30 – 02:00
An oasis in the desert: Understanding the THRß _pathway and its agonism in MASLD
– Prof Paul Yen View Bio		 02:00 – 02:20
Future of PPAR in treatment of MASLD
– Prof. Sven FrancqueView Bio		 02:20 – 02:40
Can data for bariatric surgery be extrapolated to endobariatrics for MASLD? 02:40 – 03:00
Combined Q&A 03:00 – 03:15
Tea Break 03:15 – 03:30
State of the art: Why are we not making progress with cirrhotic MASH patients?
– Prof. Arun SanyalView Bio		 03:30 – 03:50
Special considerations in managing the decompensated MASH cirrhotic patient
– TBC		 03:50 – 04:10
Managing DM in the decompensated cirrhotic – what should the MASH provider know about emerging trends in diabetes care? 04:10 – 04:30
Case based discussion
– Moderators: Dr. Mark MuthiahView Bio, Dr. Daniel Huang QingyaoView Bio		 04:30 – 05:15
Combined Q&A 05:15 – 05:30
Closing: National health policy for MASLD 05:30 – 06:00
Advancing Care in MASLD Programme Time (SGT)
Welcome Address
– Prof. Arun SanyalView Bio, Dr. Mark MuthiahView Bio		 08:30 – 08:40
Is MASLD in lean patients the same disease as in overweight and obese individuals? A clinical viewpoint
– Prof. Vincent WongView Bio		 08:40 – 09:00
Is MASLD in lean patients the same disease as in overweight and obese individuals? A pathobiological viewpoint
– Prof. Sven Francque 		09:00 – 09:20
Similarities and differences between MetALD and MASLD
– Prof. Ajay Duseja View Bio		 09:20 – 09:40
Specific aetiology SLD in the Asian context
– Dr. Daniel Huang QingyaoView Bio		 09:40 – 10:00
Combined Q&A 10:00 – 10:15
Tea Break 10:15 – 10:30
Interpreting NIT data: Lessons from NIMBLE and LITMUS
– Prof. Arun SanyalView Bio		 10:30 – 10:50
Intelligent use of NIT’s in clinical practice – moving forward and back from primary care
– Prof. Chan Wah Kheong View Bio		 10:50 – 11:10
A patient centric view of risk assessment: balancing competing risks
–Dr. Mark MuthiahView Bio		 11:10 – 11:30
Artificial Intelligence in Liver Histology: Driving Development of MASLD Therapeutics
– Prof. Dean Tai 		11:30 – 12:00
Combined Q&A 12:00 – 12:15
Lunch 12:15 – 01:30
Debate: Will incretin-based obesity treatment solve the MASLD epidemic?
–Yes:  TBC
–No: Prof. Vincent WongView Bio		 01:30 – 02:00
Future of FGF21 and THR in treatment of MASLD
– TBC		 02:00 – 02:20
Future of PPAR in treatment of MASLD
– Prof. Sven Francque		 02:20 – 02:40
Can data for bariatric surgery be extrapolated to endobariatrics for MASLD? 02:40 – 03:00
Combined Q&A 03:00 – 03:15
Tea Break 03:15 – 03:30
State of the art: Why are we not making progress with cirrhotic MASH patients?
– Prof. Arun SanyalView Bio		 03:30 – 03:50
Special considerations in managing the decompensated MASH cirrhotic patient
– TBC		 03:50 – 04:10
Managing DM in the decompensated cirrhotic – what should the MASH provider know about emerging trends in diabetes care? 04:10 – 04:30
Case based discussion
– Moderators: Dr. Mark MuthiahView Bio, Dr. Daniel Huang QingyaoView Bio		 04:30 – 05:15
Combined Q&A 05:15 – 05:30
Closing: National health policy for MASLD 05:30 – 06:00
Programme Time (SGT)
Welcome remarks Prof. Dan Yock Young 08:00 – 08:15
Session 1
NASH as a multisystem disorder- review of the evidence
– Prof. Arun Sanyal View Bio		 08:15 – 08:35
Host determinants on metabolic health and NASH progression
– Dr. Mark Muthiah View Bio		 08:35 – 08:55
Environmental drivers of end organ disease in NAFLD
– Prof. Chan Wah Kheong View Bio		 08:55 – 09:15
Discussion
– Prof. Tai E Shyong / Prof. Chan Wah Kheong View Bio		 09:15 – 09:45
Tea Break 09:45 – 10:15
Session 2
Redefining NASH as a disease of accelerated aging
– Prof. Arun Sanyal View Bio		 10:15 – 10:35
The clinical / mechanistic basis for the liver-heart connection in NASH
– Prof. Shadab Siddiqui View Bio		 10:35 – 10:55
Thyroid hormone and NASH
– Dr. Brijesh Kumar Singh		 10:55 – 11:15
Discussion
– Dr. Mark Muthiah View Bio / Prof. Chan Wah Kheong  View Bio		 11:15 – 11:45
Lunch 11:45 – 13:00
Session 3 – Controversies
Alcohol is a major confounder in assessment and management of NASH
– For the motion: Prof. Ajay Duseja  View Bio
– Against the motion: Prof. Chan Wah Kheong  View Bio		 13:00 – 13:15
13:15 – 13:30
Discussion
– Prof. Dan Yock Young View Bio / Prof. Khin Maung Win		 13:30 – 13:45
Break 13:45 – 14:00
Session 4
How to develop and evaluate a NIT
– Prof. Arun Sanyal View Bio		 14:00 – 14:20
Innovations in histological assessment- what will be the role of histology in NASH
– Prof. Arun Sanyal View Bio		 14:20 – 14:40
Status of current NITs for risk stratification and disease monitoring for NAFLD and metabolic health
– Prof. Vincent Wong View Bio		 14:40 – 15:00
Discussion
– Prof. Shadab Siddiqui View Bio / Dr. Mark Muthiah View Bio		 15:00 – 15:15
Tea Break 15:15 – 15:30
Session 5
Preparing Asia for Precision Medicine for NASH in the context of metabolic health
– Prof. Dan Yock Young View Bio		 15:30 – 15:45
Current best practises in the NASH patient
– Dr. Mark Muthiah View Bio		 15:45 – 16:00
Transplanting the decompensated NASH cirrhotic patient
– Prof. Shadab Sidiqqui View Bio		 16:00 – 16:15
Discussion
– Prof. Ajay Duseja View Bio / Prof. Khin Maung Win		 16:15 – 16:30
Challenges and Opportunities in NASH- a state of the art
– Prof. Arun Sanyal View Bio		 16:30 – 16:50

Who Should Attend?

Singapore MASLD Symposium 2024 is designed for Scientists (virologists, Immunologists), Clinician Scientists, pharmacists and Industry Experts, to exchange information on the latest research, discuss new developments in the management and treatment of MASLD

REGISTER HERE for the Combined Conference

To access SHC -e Resources REGISTER HERE or LOG IN (if you have previously registered for SHC)

Call for Abstracts

25 to 28 July 2024

8:30 am to 5:00 pm (SGT)

We invite all interested parties to present their research papers. Click on Abstracts and Posters for further information.

Abstracts will be reviewed by the Abstract Selection Committee and accepted submissions will be posted on Abstract & Poster Gallery in our website and in the Poster Hall.